https://www.biospace.com/exscientia-announces-pricing-of-304-7-million-upsized-initial-public-offering-and-160-0-million-concurrent-private-placements
Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million...
Oct 1, 2021 - Exscientia plc (Nasdaq: EXAI), today announced the pricing of its upsized initial public offering in the United States of 13,850,000 American Depositary Shares...
https://www.fiercebiotech.com/biotech/blackrock-powers-exscientia-to-100m-series-c-round-to-fund-autonomous-drug-design
BlackRock powers Exscientia to $100M series C round to fund autonomous drug design | Fierce Biotech
Mar 4, 2021 - Exscientia has raised $100 million to further d
https://www.businesswire.com/news/home/20231003737199/nl
Exscientia geeft details over de strategie voor prioriteitsbepaling van hun werkkanaal
Exscientia plc (Nasdaq: EXAI) gaf vandaag een update over haar strategie voor prioriteitenbepaling van haar werkkanaal, bedoeld om de focus, investering en i...
de strategieexscientiageeftdetails
https://www.businesswire.com/news/home/20241009324340/en/Exscientia-to-Present-New-Preclinical-Data-for-AI-designed-LSD1-and-MALT1-Inhibitors-at-ENA-2024
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelon...
https://www.ig.com/nl/aandelen/markten-aandelen/exscientia-plc
Koers Exscientia PLC | Aandeel Exscientia PLC | Exscientia PLC | IG NL
Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and... [NL]
koersexscientiaplcaandeelig
https://www.fiercebiotech.com/keyword/exscientia
Exscientia | Fierce Biotech
exscientiafiercebiotech
https://www.finder.com/stock-trading/buy-exscientia-stock
How to Buy Exscientia Stock (EXAI)
Oct 1, 2021 - We explain how to buy Exscientia Ltd ADR stock, compare the best stock trading platforms and use a detailed analysis to learn about (EXAI).
how to buyexscientiastockexai
https://www.businesswire.com/news/home/20240828867760/en/Exscientia-to-Present-at-the-Morgan-Stanley-22nd-Annual-Global-Healthcare-Conference
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a firesid...
at themorgan stanley
https://www.fiercebiotech.com/biotech/merck-kgaa-doubles-ai-partners-tapping-benevolentai-and-exscientia-drug-discovery-push
Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery
Sep 20, 2023 - The deals are collectively worth more than $30 million upfront and $1 billion in potential milestones.
merck kgaafor aitapsexscientiadrug
https://www.fiercebiotech.com/medtech/exscientia-ai-artificial-intelligence-study-results-blood-cancer-hematology-oncology
Exscientia AI study spots which blood cancer therapies work and which don't | Fierce Biotech
Oct 14, 2021 - A group of international researchers and the artificial intelligence developers at Exscientia have shown that an AI approach to personalized medicine could...
https://www.techtarget.com/pharmalifesciences/news/366606944/Sanofi-Exscientia-to-Research-Develop-Small-Molecule-Drugs
Sanofi, Exscientia to Research, Develop Small Molecule Drugs | TechTarget
Sanofi and Exscientia will identify and select target small molecule drug candidates for various chronic diseases and diseases with unmet medical needs.
small molecule drugsto researchsanofiexscientiadevelop
https://apply.workable.com/exscientia/?not_found=true
Exscientia - Current Openings
exscientiacurrentopenings
https://www.biospace.com/exscientia-announces-sixth-molecule-created-through-generative-ai-platform-to-enter-clinical-stage
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage...
May 16, 2023 - Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.
generative ai platform
https://www.businesswire.com/news/home/20220405005276/en/Michael-Krams-M.D.-Joins-Exscientia-as-Chief-Quantitative-Medicine-Officer
Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role,...
m dmichaelkramsjoins
https://www.mdanderson.org/newsroom/md-anderson-exscientia-launch-strategic-collaboration-leverage-ai-developing-novel-oncology-treatments.h00-159544479.html
Collaboration to leverage AI in drug development announced by MD Anderson, Exscientia | UT MD...
MD Anderson and Exscientia today announced a collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of...